Pediatric calfactant in acute respiratory distress syndrome trial

Douglas F. Willson, Neal J. Thomas, Robert Tamburro, Edward J Truemper, Jonathon Truwit, Mark Conaway, Christine Traul, Edmund E. Egan

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Rationale: Our previous studies in children with acute lung injury/ acute respiratory distress syndrome demonstrated improved outcomes with exogenous surfactant (calfactant) administration. Sample sizes in those studies were small, however, and the subject populations heterogeneous, thus making recommendations tenuous. Objective: To investigate the efficacy of surfactant administration in a larger, more homogenous population of children with lung injury/acute respiratory distress syndrome due to direct lung injury. Design and Setting: Masked, randomized, placebo-controlled trial in 24 children's hospitals in six different countries. Patients and Methods: Children 37 weeks postconception to 18 years old with lung injury/acute respiratory distress syndrome due to direct lung injury were randomized to receive up to three doses of 30 mg/cm height of surfactant (calfactant) versus placebo (air) within 48 hours of intubation and initiation of mechanical ventilation. The primary outcome was mortality at 90 days. Ventilator-free days, changes in oxygenation, and adverse events were also assessed. Results: The study was stopped at the sponsor's request after the second interim analysis for presumed futility. A total of 110 subjects were enrolled, with consent withdrawn from one whose data are unavailable. There were no significant differences between groups except in hospital-free days (10.4 ± 7.8 placebo vs 6.4 ± 7.8 surfactant; p = 0.01). Overall 90-day mortality was 11% (seven surfactant, five placebo). No immediate improvement in oxygenation was associated with surfactant administration. Conclusions: Surfactant did not improve outcomes relative to placebo in this trial of children with direct lung injury/acute respiratory distress syndrome. Differences in concentration of the surfactant, failure to recruit the lung during surfactant administration, or using two rather than four position changes during administration are possible explanations for the difference from previous studies. Exogenous surfactant cannot be recommended at this time for children with direct lung injury/acute respiratory distress syndrome.

Original languageEnglish (US)
Pages (from-to)657-665
Number of pages9
JournalPediatric Critical Care Medicine
Volume14
Issue number7
DOIs
StatePublished - Jan 1 2013

Fingerprint

Adult Respiratory Distress Syndrome
Surface-Active Agents
Pediatrics
Lung Injury
Placebos
calfactant
Medical Futility
Mortality
Acute Lung Injury
Mechanical Ventilators
Artificial Respiration
Intubation
Sample Size
Population
Randomized Controlled Trials
Air
Lung

Keywords

  • Acute lung injury
  • Acute respiratory distress syndrome
  • Calfactant
  • Direct lung injury
  • Hypoxemia index
  • Oxygen saturation index
  • Recruitment maneuver
  • Respiratory failure
  • Surfactant

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Critical Care and Intensive Care Medicine

Cite this

Willson, D. F., Thomas, N. J., Tamburro, R., Truemper, E. J., Truwit, J., Conaway, M., ... Egan, E. E. (2013). Pediatric calfactant in acute respiratory distress syndrome trial. Pediatric Critical Care Medicine, 14(7), 657-665. https://doi.org/10.1097/PCC.0b013e3182917b68

Pediatric calfactant in acute respiratory distress syndrome trial. / Willson, Douglas F.; Thomas, Neal J.; Tamburro, Robert; Truemper, Edward J; Truwit, Jonathon; Conaway, Mark; Traul, Christine; Egan, Edmund E.

In: Pediatric Critical Care Medicine, Vol. 14, No. 7, 01.01.2013, p. 657-665.

Research output: Contribution to journalArticle

Willson, DF, Thomas, NJ, Tamburro, R, Truemper, EJ, Truwit, J, Conaway, M, Traul, C & Egan, EE 2013, 'Pediatric calfactant in acute respiratory distress syndrome trial', Pediatric Critical Care Medicine, vol. 14, no. 7, pp. 657-665. https://doi.org/10.1097/PCC.0b013e3182917b68
Willson, Douglas F. ; Thomas, Neal J. ; Tamburro, Robert ; Truemper, Edward J ; Truwit, Jonathon ; Conaway, Mark ; Traul, Christine ; Egan, Edmund E. / Pediatric calfactant in acute respiratory distress syndrome trial. In: Pediatric Critical Care Medicine. 2013 ; Vol. 14, No. 7. pp. 657-665.
@article{8f4224791db446b395c1c7d76b91b2de,
title = "Pediatric calfactant in acute respiratory distress syndrome trial",
abstract = "Rationale: Our previous studies in children with acute lung injury/ acute respiratory distress syndrome demonstrated improved outcomes with exogenous surfactant (calfactant) administration. Sample sizes in those studies were small, however, and the subject populations heterogeneous, thus making recommendations tenuous. Objective: To investigate the efficacy of surfactant administration in a larger, more homogenous population of children with lung injury/acute respiratory distress syndrome due to direct lung injury. Design and Setting: Masked, randomized, placebo-controlled trial in 24 children's hospitals in six different countries. Patients and Methods: Children 37 weeks postconception to 18 years old with lung injury/acute respiratory distress syndrome due to direct lung injury were randomized to receive up to three doses of 30 mg/cm height of surfactant (calfactant) versus placebo (air) within 48 hours of intubation and initiation of mechanical ventilation. The primary outcome was mortality at 90 days. Ventilator-free days, changes in oxygenation, and adverse events were also assessed. Results: The study was stopped at the sponsor's request after the second interim analysis for presumed futility. A total of 110 subjects were enrolled, with consent withdrawn from one whose data are unavailable. There were no significant differences between groups except in hospital-free days (10.4 ± 7.8 placebo vs 6.4 ± 7.8 surfactant; p = 0.01). Overall 90-day mortality was 11{\%} (seven surfactant, five placebo). No immediate improvement in oxygenation was associated with surfactant administration. Conclusions: Surfactant did not improve outcomes relative to placebo in this trial of children with direct lung injury/acute respiratory distress syndrome. Differences in concentration of the surfactant, failure to recruit the lung during surfactant administration, or using two rather than four position changes during administration are possible explanations for the difference from previous studies. Exogenous surfactant cannot be recommended at this time for children with direct lung injury/acute respiratory distress syndrome.",
keywords = "Acute lung injury, Acute respiratory distress syndrome, Calfactant, Direct lung injury, Hypoxemia index, Oxygen saturation index, Recruitment maneuver, Respiratory failure, Surfactant",
author = "Willson, {Douglas F.} and Thomas, {Neal J.} and Robert Tamburro and Truemper, {Edward J} and Jonathon Truwit and Mark Conaway and Christine Traul and Egan, {Edmund E.}",
year = "2013",
month = "1",
day = "1",
doi = "10.1097/PCC.0b013e3182917b68",
language = "English (US)",
volume = "14",
pages = "657--665",
journal = "Pediatric Critical Care Medicine",
issn = "1529-7535",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - Pediatric calfactant in acute respiratory distress syndrome trial

AU - Willson, Douglas F.

AU - Thomas, Neal J.

AU - Tamburro, Robert

AU - Truemper, Edward J

AU - Truwit, Jonathon

AU - Conaway, Mark

AU - Traul, Christine

AU - Egan, Edmund E.

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Rationale: Our previous studies in children with acute lung injury/ acute respiratory distress syndrome demonstrated improved outcomes with exogenous surfactant (calfactant) administration. Sample sizes in those studies were small, however, and the subject populations heterogeneous, thus making recommendations tenuous. Objective: To investigate the efficacy of surfactant administration in a larger, more homogenous population of children with lung injury/acute respiratory distress syndrome due to direct lung injury. Design and Setting: Masked, randomized, placebo-controlled trial in 24 children's hospitals in six different countries. Patients and Methods: Children 37 weeks postconception to 18 years old with lung injury/acute respiratory distress syndrome due to direct lung injury were randomized to receive up to three doses of 30 mg/cm height of surfactant (calfactant) versus placebo (air) within 48 hours of intubation and initiation of mechanical ventilation. The primary outcome was mortality at 90 days. Ventilator-free days, changes in oxygenation, and adverse events were also assessed. Results: The study was stopped at the sponsor's request after the second interim analysis for presumed futility. A total of 110 subjects were enrolled, with consent withdrawn from one whose data are unavailable. There were no significant differences between groups except in hospital-free days (10.4 ± 7.8 placebo vs 6.4 ± 7.8 surfactant; p = 0.01). Overall 90-day mortality was 11% (seven surfactant, five placebo). No immediate improvement in oxygenation was associated with surfactant administration. Conclusions: Surfactant did not improve outcomes relative to placebo in this trial of children with direct lung injury/acute respiratory distress syndrome. Differences in concentration of the surfactant, failure to recruit the lung during surfactant administration, or using two rather than four position changes during administration are possible explanations for the difference from previous studies. Exogenous surfactant cannot be recommended at this time for children with direct lung injury/acute respiratory distress syndrome.

AB - Rationale: Our previous studies in children with acute lung injury/ acute respiratory distress syndrome demonstrated improved outcomes with exogenous surfactant (calfactant) administration. Sample sizes in those studies were small, however, and the subject populations heterogeneous, thus making recommendations tenuous. Objective: To investigate the efficacy of surfactant administration in a larger, more homogenous population of children with lung injury/acute respiratory distress syndrome due to direct lung injury. Design and Setting: Masked, randomized, placebo-controlled trial in 24 children's hospitals in six different countries. Patients and Methods: Children 37 weeks postconception to 18 years old with lung injury/acute respiratory distress syndrome due to direct lung injury were randomized to receive up to three doses of 30 mg/cm height of surfactant (calfactant) versus placebo (air) within 48 hours of intubation and initiation of mechanical ventilation. The primary outcome was mortality at 90 days. Ventilator-free days, changes in oxygenation, and adverse events were also assessed. Results: The study was stopped at the sponsor's request after the second interim analysis for presumed futility. A total of 110 subjects were enrolled, with consent withdrawn from one whose data are unavailable. There were no significant differences between groups except in hospital-free days (10.4 ± 7.8 placebo vs 6.4 ± 7.8 surfactant; p = 0.01). Overall 90-day mortality was 11% (seven surfactant, five placebo). No immediate improvement in oxygenation was associated with surfactant administration. Conclusions: Surfactant did not improve outcomes relative to placebo in this trial of children with direct lung injury/acute respiratory distress syndrome. Differences in concentration of the surfactant, failure to recruit the lung during surfactant administration, or using two rather than four position changes during administration are possible explanations for the difference from previous studies. Exogenous surfactant cannot be recommended at this time for children with direct lung injury/acute respiratory distress syndrome.

KW - Acute lung injury

KW - Acute respiratory distress syndrome

KW - Calfactant

KW - Direct lung injury

KW - Hypoxemia index

KW - Oxygen saturation index

KW - Recruitment maneuver

KW - Respiratory failure

KW - Surfactant

UR - http://www.scopus.com/inward/record.url?scp=84898733562&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898733562&partnerID=8YFLogxK

U2 - 10.1097/PCC.0b013e3182917b68

DO - 10.1097/PCC.0b013e3182917b68

M3 - Article

VL - 14

SP - 657

EP - 665

JO - Pediatric Critical Care Medicine

JF - Pediatric Critical Care Medicine

SN - 1529-7535

IS - 7

ER -